Toggle Main Menu Toggle Search

Open Access padlockePrints

Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients

Lookup NU author(s): Dr John Steer, Dr Carlos Echevarria, Professor Stephen BourkeORCiD, Dr Nicholas Lane

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


Abstract

© 2024, European Respiratory Society. All rights reserved.Background Exacerbations of COPD (ECOPD) have a major impact on patients and healthcare systems across the world. Precise estimates of the global burden of ECOPD on mortality and hospital readmission are needed to inform policy makers and aid preventive strategies to mitigate this burden. The aims of the present study were to explore global in-hospital mortality, post-discharge mortality and hospital readmission rates after ECOPD-related hospitalisation using an individual patient data meta-analysis (IPDMA) design. Methods A systematic review was performed identifying studies that reported in-hospital mortality, postdischarge mortality and hospital readmission rates following ECOPD-related hospitalisation. Data analyses were conducted using a one-stage random-effects meta-analysis model. This study was conducted and reported in accordance with the PRISMA-IPD statement. Results Data of 65 945 individual patients with COPD were analysed. The pooled in-hospital mortality rate was 6.2%, pooled 30-, 90- and 365-day post-discharge mortality rates were 1.8%, 5.5% and 10.9%, respectively, and pooled 30-, 90- and 365-day hospital readmission rates were 7.1%, 12.6% and 32.1%, respectively, with noticeable variability between studies and countries. Strongest predictors of mortality and hospital readmission included noninvasive mechanical ventilation and a history of two or more ECOPD-related hospitalisations


Publication metadata

Author(s): Waeijen-Smit K, Crutsen M, Keene S, Miravitlles M, Crisafulli E, Torres A, Mueller C, Schuetz P, Ringbaek TJ, Fabbian F, Mekov E, Harries TH, Lun C-T, Ergan B, Esteban C, Quintana Lopez JM, Lopez-Campos JL, Chang CL, Hancox RJ, Shafuddin E, Ellis H, Janson C, Ulrik CS, Gudmundsson G, Epstein D, Dominguez J, Lacoma A, Osadnik C, Alia I, Spannella F, Karakurt Z, Mehravaran H, Utens C, de Kruif MD, San Ko FW, Trethewey SP, Turner AM, Bumbacea D, Murphy PB, Vermeersch K, Zilberman-Itskovich S, Steer J, Echevarria C, Bourke SC, Lane N, de Batlle J, Sprooten RTM, Russell R, Faverio P, Cross JL, Prins HJ, Spruit MA, Simons SO, Houben-Wilke S, Franssen FME

Publication type: Article

Publication status: Published

Journal: ERJ Open Research

Year: 2024

Volume: 10

Issue: 1

Online publication date: 26/02/2024

Acceptance date: 16/12/2023

Date deposited: 09/04/2024

ISSN (electronic): 2312-0541

Publisher: European Respiratory Society

URL: https://doi.org/10.1183/23120541.00838-2023

DOI: 10.1183/23120541.00838-2023


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
#90030355
Health∼Holland
LSHI19003
Top Sector Life Sciences & Health
ZonMWAQ10

Share